Fusion Antibodies Plc stock analysis
Want to see GB:FAB full AI Analyst Report?
Fusion Antibodies Plc (FAB) Share Price & Analysis
FAB Stock Chart & Stats
- Day’s Range
- GBX 3.56 - GBX 4.50
- 52-Week Range
- GBX 3.50 - GBX 20.00
- Previous Close
- GBX 4.25
- Volume
- N/A
- Average Volume (3M)
- 903.25K
- Market Cap
- GBP 5.32M
- Enterprise Value
- GBP 13.92M
- Total Cash (Recent Filing)
- GBP 1.04M
- Total Debt (Recent Filing)
- GBP 331.00K
- Price to Earnings (P/E)
- ―
- Beta
- -0.74
- Next Earnings
- Dec 07, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Rebound
The strong latest-year revenue rebound indicates renewed customer demand for Fusion Antibodies’ specialized discovery and development services. If sustained, higher activity can improve operating leverage, support broader client engagement, and provide a foundation for scaling the business over the next several quarters.
Gross Margin Improvement
The substantial gross-margin improvement shows that recent revenue is being generated with better direct economics than in prior periods. Maintaining this level would strengthen contribution from projects, improve the potential path toward breakeven, and make future revenue growth more valuable to shareholders.
Contained Leverage
Relatively contained leverage gives the company more financial flexibility than a heavily debt-funded balance sheet would provide. Lower debt pressure can preserve strategic options, reduce the burden of interest and refinancing, and allow management to focus available resources on rebuilding operations and reaching sustainable scale.
Bears Say
Persistent Operating Losses
Large operating and net losses show that the recent revenue recovery has not yet translated into a sustainable earnings model. Continued losses can consume equity, limit internally funded investment, and indicate that the company still needs substantial operating improvement before growth produces durable shareholder returns.
Ongoing Cash Burn
Negative operating and free cash flow means the business is not currently funding its activities from customer receipts and remains reliant on external funding. Even with improved cash burn relative to earlier periods, prolonged deficits can constrain investment, reduce resilience, and increase financing dependence.
Volatile Revenue And Scale Risk
The multi-year revenue volatility makes it difficult to treat the latest rebound as an established growth trajectory. Combined with persistent losses, this suggests the specialized service platform has not yet achieved durable scale, leaving future performance sensitive to the consistency of project demand.
Fusion Antibodies Plc News
Fusion Antibodies Wins Complex Antibody Development Contract with Global Pharma Client
Fusion Antibodies Plc ( ($GB:FAB) ) has provided an update. Fusion Antibodies plc, a Belfast-based CRO focused on antibody engineering and pre-clinical development for therapeutic and diagnostic uses, provides end-to-end
Fusion Antibodies AGM Resolutions Passed as Company Targets Expanding Antibody Market
Fusion Antibodies Plc ( ($GB:FAB) ) has provided an update. Fusion Antibodies plc, a specialist in antibody engineering and pre-clinical discovery services for pharma and diagnostics clients, reported that all
Fusion Antibodies launches revamped customer-focused website to showcase antibody services
Fusion Antibodies Plc ( ($GB:FAB) ) has issued an announcement. Fusion Antibodies plc, a specialist in pre-clinical antibody discovery and engineering, has launched a redesigned customer-focused website aimed at better
Fusion Antibodies to unveil annual results with open investor presentation
Fusion Antibodies Plc ( ($GB:FAB) ) has issued an announcement. Fusion Antibodies Plc, a Belfast-based specialist in pre-clinical antibody discovery and engineering, operates as a contract research organisation serving therapeutic
FAB FAQ
What was Fusion Antibodies Plc’s price range in the past 12 months?
What is Fusion Antibodies Plc’s market cap?
When is Fusion Antibodies Plc’s upcoming earnings report date?
How were Fusion Antibodies Plc’s earnings last quarter?
Is Fusion Antibodies Plc overvalued?
Does Fusion Antibodies Plc pay dividends?
What is Fusion Antibodies Plc’s EPS estimate?
How many shares outstanding does Fusion Antibodies Plc have?
What happened to Fusion Antibodies Plc’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Fusion Antibodies Plc?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Fusion Antibodies Plc
Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology and infectious diseases, serving a global clientele across the United Kingdom, broader Europe, and North America. Its comprehensive suite of offerings encompasses monoclonal antibody discovery and advancement, antibody sequencing and engineering, and a distinct platform for antibody humanization and rational affinity maturation. Additionally, Fusion Antibodies provides recombinant protein expression, stable cell line development, and cGMP-compliant scale-up services. Clients span the pharmaceutical, biotechnology, and diagnostic sectors. Notably, the company maintains a collaborative partnership with Celonic AG. Established in 2000, Fusion Antibodies plc is headquartered in Belfast, United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Adrian Robert Kinkaid
- Employees
- 27
- Website
- www.fusionantibodies.com
- Address
- Springbank Industrial Estate, Belfast, BF, BT17 0QL, GB
Fusion Antibodies Plc (FAB) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 5 | 15 |
| Technical Analysis | 2 | 4 | 4 |
| Moving Averages | 0 | 1 | 11 |










